Anti-TNFα Drug Levels in Patients with Rheumatoid Arthritis and Spondyloarthritis.

Knowledge of the levels of anti-TNFα drugs can modify treatment in patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA). To compare the levels of anti-TNFα in patients with RA vs SpA, in different clinical situations. A retrospective, observational study was conducted. Levels of anti-TNFα and the presence of anti-drug antibodies were measured in consecutively selected patients, using the ELISA technique. Fifty-three, 73 and 78 patients treated with infliximab, adalimumab and etanercept were studied, respectively. The median drug levels in patients using standard doses were infliximab 2.2μg/ml (1.4-5.2), adalimumab 4.9μg/ml (0.8-8.9) and etanercept 3.1μg/ml (2.3-4.4). There were no differences in drug levels according to disease activity but we found differences in etanercept and infliximab levels according to DMARD use. Levels of anti-TNFα drugs will change with DMARD treatment. Copyright © 2021 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.

Citation

Erardo Meriño-Ibarra, Francisco Javier Manero Ruíz. Anti-TNFα Drug Levels in Patients with Rheumatoid Arthritis and Spondyloarthritis. Reumatologia clinica. 2021 Sep 06

PMID: 34503928

search → result